Paytm parent One 97 Communications Ltd., Mazagon Dock Shipbuilders Ltd., DMart operator Avenue Supermarts Ltd., and Swiggy Ltd. were among the top companies on brokerages' radar on Monday.
Analysts have shared their views on DMart's June quarter earnings.
UBS has hiked the target price on Paytm, while Mazagon Dock and Swiggy have received new coverage from brokerages.
NDTV Profit tracked analysts' views on various stocks and sectors. Here are the analyst calls to keep an eye out for today.
Brokerages On Avenue Supermarts Q1 Results
Morgan Stanley
Maintain 'Underweight' and hike target price to Rs 3,350 from Rs 3,260.
Q1: Miss estimates, multiple headwinds continue.
Higher competitive intensity and Avenue's efforts to fight competition and build capabilities continue to weigh on the business.
Believe the current results and commentary add to the ongoing de-rating in the stock.
Macquarie
Maintain 'Underperform' with target price of Rs 3,100.
Q1 margin miss; competition concerns sustain.
Liked the 7.1% same-store-sales growth and the sequentially lower losses for DMart Ready.
Did not like the 100-150 basis points (bps) hit to Q1 sales growth from high deflation of staples/non-food products, which will continue for a few quarters.
JPMorgan
Maintain 'Neutral' with target price of Rs 4,150.
Margin weakness sustains amidst higher investments.
View the intent of accelerated store additions and E-commerce capacity build-out favorably.
Next catalyst would be the management interaction held annually over the coming weeks.
HSBC
Maintain 'Reduce' and hike target price to Rs 3,600 from Rs 3,500.
Ebitda and margins were slightly below muted consensus.
Competitive intensity elevated, impact visible.
Value proposition remains strong but has diminished over time.
Intense competition has presented a challenge for DMART.
It has become a trade-off between SSSG and margin stability.
UBS On Paytm
Maintain 'Neutral' and hike target price to Rs 1,050 from Rs 1,000.
Net profit breakeven likely in Q1
Payments growth is slowing from a high base.
Would view Paytm's PAT turning positive in FY26 as a re-rating catalyst, given its material discount to Indian internet peers.
But, not receiving a payment aggregator licence so far and weak customer additions remain concerns.
AMSEC On Mazagon Dock
Initiate 'Sell' with a target price of Rs 2,100.
Current orderbook is insufficient for a strong growth in the near term, especially FY27 and FY28.
Newer orders may be executed only post-FY28.
The absence of near-term triggers raises concerns over premium valuations.
Elara Securities On Swiggy
Initiate 'Accumulate' with a target price of Rs 450.
Food delivery shows improvement.
Instamart has a long haul for positive adjusted Ebitda.
Huge total addressable market (TAM) to capture growth.
Swiggy has a large growth opportunity and execution headroom.
B&K Securities On Landmark Cars
Initiate 'Buy' with a target price of Rs 820.
Bottoming out of profit cycle and ready to revive.
Cost rationalisation activities complete.
Remains a business with high entry barriers backed by experienced management.
Jefferies On Supreme Industries
Maintain 'Buy' with a target price of Rs 5,150.
Despite a high base, volume growth revived to 10% YoY in April-May 2025, possibly led by channel restocking.
PVC price is near 15-year lows.
Premium VAS sales grew by 12% YoY, which bodes well for margins.
In July 2025, received BPCL's order for composite LPG cylinders.
Pipes capacity to reach 940K MT in FY26e.
View Supreme Industries as a play on housing, capex, agriculture; estimate 23% EPS CAGR over FY25-28.
HSBC On Oil Marketing Companies
Recent news reports on LPG subsidy indicate likely support for OMCs.
This news is likely to provide support to OMC stocks.
In the interim, oil prices remain rangebound, auto fuel demand stable, and refining margins decent.
Potential for higher marketing margins on downside risk in oil prices.
Auto fuel demand maintains momentum.
JM Financial On Gujarat Fluorochemicals
Initiate 'Hold' with a target price of Rs 3,600.
Multiple growth levers to drive top-line over FY25-28.
Revenue, Ebitda and net profit CAGR expected at 23%, 27% and 27% over FY25-28.
New fluoropolymers to be the major driver of the next leg of growth.
Value-added PTFE volumes to increase, leading to higher realisations and margins.
HFC-32 capacity addition to cater to global demand.
HFC-410a to provide additional revenues in the ref gas portfolio.
Battery materials portfolio to supercharge long-term revenue growth.
Bulk chemicals enables vertical integration along with steady revenues.
Fluorospecialty business to provide steady revenues.
Morgan Stanley On Pharma
Sun Pharma – Initiate 'Overweight' with a target price of Rs 1,960.
Lupin – Initiate 'Equal-weight' with a target price of Rs 2,096.
Dr Reddy – Initiate 'Equal-weight' with a target price of Rs 1,298.
Cipla – Initiate 'Underweight' with a target price of Rs 1,400.
Expect earnings growth to taper off over FY25-27.
Strong balance sheets should support investments into peptides, speciality, and biosimilars.
Overweight Sun Pharma given healthy speciality pipeline, chronic-focussed India business, and strong balance sheet.
Equal-weight Lupin as expect a strong first half, but see US competition risk in key products afterwards.
See FY26 as a transition year for Dr Reddy and Cipla, as revenue from highly profitable gRevlimid tapers.
Semaglutide ramp could be an upside surprise for Dr Reddy.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
